Research Paper

Lens autophagy protein ATG16L1: a potential target for cataract treatment

Yilei Cui1*, Xiaoning Yu1*, Jing Bao1, Xiyuan Ping1, Silu Shi1, Yuxin Huang1, Qichuan Yin1, Hao Yang1, Ruoqi Chen1, Ke Yao1, Xiangjun Chen2*, Xingchao Shentu1*

1. Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou310009, China.
2. The Institute of Translational Medicine, Zhejiang University, Hangzhou310020, China.

*These authors contributed equally to this work as co-first authors.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Abstract

_Rationale:_ Cataract is the leading cause of blindness and low vision worldwide, yet its pathological mechanism is not fully understood. Although macroautophagy/autophagy is recognized as essential for lens homeostasis and has shown potential in alleviating cataracts, its precise mechanism remains unclear. Uncovering the molecular details of autophagy in the lens could provide targeted therapeutic interventions alongside surgery.

_Methods:_ We monitored autophagic activities in the lens and identified the key autophagy protein ATG16L1 by immunofluorescence staining, Western blotting, and transmission electron microscopy. The regulatory mechanism of ATG16L1 ubiquitination was analyzed by co-immunoprecipitation and Western blotting. We used the crystal structure of E3 ligase gigaxonin and conducted the docking screening of a chemical library. The effect of the identified compound riboflavin was tested in vitro in cells and in vivo animal models.

_Results:_ We used HLE cells and connexin 50 (cx50)-deficient cataract zebrafish model and confirmed that ATG16L1 was crucial for lens autophagy. Stabilizing ATG16L1 by attenuating its ubiquitination-dependent degradation could promote autophagy activity and relieve cataract phenotype in cx50-deficient zebrafish. Mechanistically, the interaction between E3 ligase gigaxonin and ATG16L1 was weakened during this process. Leveraging these mechanisms, we identified riboflavin, an E3 ubiquitin ligase-targeting drug, which suppressed ATG16L1 ubiquitination, promoted autophagy, and ultimately alleviated the cataract phenotype in autophagy-related models.

_Conclusions:_ Our study identified an unrecognized mechanism of cataractogenesis involving ATG16L1 ubiquitination in autophagy regulation, offering new insights for treating cataracts.

Keywords: ATG16L1; autophagy; cataract; ubiquitination; E3 ligase

Introduction

Cataracts result from the opacification of the lens and are the leading cause of blindness and low vision globally [1]. To date, the only established treatment is cataract surgery, which might cause a series of complications, such as posterior capsule opacification and endophthalmitis [2]. Thus, there is a pressing need to elucidate underlying molecular pathogenesis and identify effective targeted therapies.

Autophagy is an evolutionarily conserved self-degradation process crucial in maintaining intracellular homeostasis [3, 4]. In the lens, constitutively activated autophagy is observed throughout the differentiation of lens epithelial and fiber cells involved in organelle degradation and maintaining transparency [5, 6]. Mutations in autophagy-related genes, such as FYCO1, EFG5, and
CHMP4B, have been reported in congenital cataract patients [7-9]. Autophagy defects in cataract-associated genes have also been confirmed in transgenic mouse models [10-12]. For instance, mutations in TDRD7, a gene responsible for congenital cataracts, disrupt autophagosome fusion with lysosomes, resulting in a failure to remove organelles in lens fiber cells [13]. Autophagy disturbance was also reported in age-related cataracts, with a prevalence of 54.38% in patients above age 60 [14]. These findings suggest the intricate role of autophagy in maintaining lens transparency and identify cataracts as an autophagy defect-related disease. However, the complex regulatory network of autophagy and its aberrancy, causing lens opacity, remains unclear.

More than 30 evolutionarily conserved autophagy-related genes (ATGs) are believed to be involved in the regulatory network, with ATG16L1 being a key determinant of autophagosome elongation [15, 16]. It interacts with the ATG5-ATG12 conjugate to assemble the E3-like complex and facilitates LC3 lipidation for membrane biogenesis in higher eukaryotes [17, 18]. Although its autophagic function has been extensively studied, little is known about the mechanisms regulating the ATG16L1 protein.

A recent study confirmed that ATG16L1 turnover is a ubiquitin-dependent process in COS 7 cells [19]. In this study, we demonstrated that ubiquitination of ATG16L1 is crucial for regulating the autophagy pathway in the lens. We found that stabilizing ATG16L1 by attenuating its ubiquitination-dependent degradation could promote autophagy and alleviate the cataract phenotype in connexin 50 (cx50)-deficient zebrafish [4], a typical cataract model with a defective autophagy process. Mechanistically, this process weakens the interaction between E3 ubiquitin ligase gigaxionin and ATG16L1. E3 ubiquitin ligase-targeting drugs, especially riboflavin, were effective in reducing ATG16L1 ubiquitination and activating autophagy, alleviating the cataract phenotype in zebrafish with cx50 defect. Furthermore, we verified this mechanism in two other autophagy-related cataract models, including one induced by oxidative stress. Collectively, our results provide a promising strategy for a potential non-surgical cataract treatment.

Materials and Methods

Animals

AB WT and cx50-deficient zebrafish (Ensembl ID: ENSDARG00000015076), obtained from China Zebrafish Resource Center, were used in this study. Zebrafish (no defined gender until 60 days post-fertilization) were maintained in a circulating water system at 28.5 °C with a daily cycle of 14 hours of light/10 hours of dark. Embryos were collected and maintained in E3 media with methylene blue in a thermostatic incubator.

Our previous study identified that cx50 deficiency in zebrafish results in defective autophagy, causing severe defects in organelle degradation and ultimately leading to cataract formation [20]. Therefore, the cx50-deficient zebrafish was used as a cataract model with an autophagy defect in the present study.

In the rescue experiment, 80 µM riboflavin or DMSO was added to zebrafish at 12 hours post-fertilization (hpf), with media replacement every 24 hours until 72 hpf. For microinjection, 3-4 nl of ATG16L1 plasmid (50 ng/µl) was injected into fertilized eggs, and zebrafish were collected at 72 hpf.

For the H2O2-induced cataract zebrafish model, 2 µl of 3% H2O2 was injected into the lens anterior chamber of zebrafish using 32G needles as in previous studies [21]. Control fish were injected with 0.5 µl of PBS. The culture medium of zebrafish was supplemented with or without 80 µM riboflavin-loaded liposomes for 24 hours and then placed in a 10 cm dish for further observation and photography.

Six-week-old Sprague-Dawley rats (male, 200 g, Shanghai SLAC Laboratory Animal Co., Ltd.) were used for the hypothermic cataract rat model. The lenses were obtained from post-mortem rats and incubated at 4 °C in Hibernate™-A Medium (A1247501; Thermo Fisher Scientific, Waltham, MA, USA) containing 10% fetal bovine serum (FBS) (AusgeneX, Brisbane, Australia) and 1% penicillin-streptomycin for 24 h. Subsequently, the lenses were washed 3 times with PBS and incubated in DMEM (10-090-CV; Corning, New York, USA) containing 10% fetal bovine serum (FBS) (AusgeneX, Brisbane, Australia) and 1% penicillin-streptomycin for 24 h. Subsequently, the lenses were washed 3 times with PBS and incubated in DMEM (10-090-CV; Corning, New York, USA) supplemented with 10% FBS with or without 80 µM riboflavin for 24 h. Following rewarming treatment, the rat lenses were placed in an Extracellular Solution (C0216; Beyotime Biotechnology, Shanghai, China) for further observation and photography.

All animal experiments in this study were conducted in accordance with the ARRIVE guidelines and were approved by Zhejiang University Animal Care and Use Committee protocols (No. 2019-069).

Cell culture and transfections

HLE cells (SRA01-04) were obtained from the RIKEN Cell Bank (RCB1591), and HEK293T cells were acquired from ATCC (CRL-3216). The cells were cultured in DMEM (10-090-CV; Corning) containing 10% FBS. For RNA interference, the siRNA was
transfected using Lipofectamine 3000 (L3000015; Invitrogen, Carlsbad, CA, USA) for 48 h, according to the manufacturer’s instructions. Subsequently, RNAi efficiency was measured by Q-PCR and Western blotting. siRNAs used were: CX50 siRNA#1: GCCAGGTCAGACGATCTAA. CX50 siRNA#2: TGTCCCTATTCTCAACGT. For gene overexpression, the cells were transiently transfected with the indicated plasmids using Lipofectamine 3000 for 24 h. Other reagents used were as follows: chloroquine (CQ, HY-17589A), 30 µM, 6 h; MG132 (HY-13259), 10 µM, 6 h; riboflavin (HY-B0456), 80 µM, 24 h were purchased from MedChemexpress, New Jersey, USA. Riboflavin-loaded liposomes, 80 µM, 24 h were acquired from AVT Pharmaceutical Technology.

**Immunoprecipitation (IP) and Western blotting**

For IP, the cells were lysed in RIPA buffer (P0013; Beyotime Biotechnology) with 1% PMSF and then centrifuged at 12000 g for 30 min. The resultant supernatant was mixed with the indicated antibodies at 4 °C for 4 h, followed by adding A/G magnetic beads (B23202; Bimake, Houston, Texas, USA) at 4 °C overnight. After washing with RIPA lysis buffer 3 times, the beads were resuspended in 50 μl of 2× loading buffer and subjected to Western blotting, as described previously [22]. Briefly, equal amounts of samples were separated by SDS-PAGE, transferred to PVDF membranes, and incubated with appropriate antibodies. The following antibodies were used: anti-ATG16L1 (PM040; MBL, Japan), anti-LC3 (3868; Cell Signaling Technology, Danvers, MA, USA), anti-P62 (ab56416; Abcam, Cambridge, UK), anti-CX50 (33-4300; Invitrogen, Carlsbad, CA, USA), anti-GAPDH (60004-Ig; Proteintech, Chicago, Illinois, USA), anti-ATG5 (12994; Cell Signaling Technology), anti-Flag (F3165; MilliporeSigma, Saint Louis, Missouri, USA), anti-HA (ab9110; Abcam), anti-Ubiquitin (PM040; MBL), and anti-MYC (2276; Cell Signaling Technology). The blots were analyzed using an image analysis system.

**RNA extraction and real-time RT-PCR**

Total RNA extraction and real-time RT-PCR were conducted as described previously [22]. The primers used were as follows:

- **ATG16L1-F**: CAGGCACGAGATAAGTCCCG,
- **ATG16L1-R**: AACTCCCCACGTTCCTTGTT;
- **ATG5-F**: AAAGATGTGCTTCCAGATGTT;
- **ATG5-R**: CACTTTGTCAGTTACCAAGTC;
- **ATG12-F**: TAGAGCC AACACGAACCATCC;
- **ATG12-R**: CACTGCCAAA ACACTCATAGAGA.

**Immunofluorescence**

The HLE cells or zebrafish were fixed with 4% paraformaldehyde (P1110, Solarbio) for 15 min at room temperature and then blocked in PB5 containing 10% goat serum albumin and 0.4% Triton X-100 (P0096, Beyotime Biotechnology) for 1 h. Then, the cells were incubated with the corresponding primary, secondary antibodies and DAPI (C0065, Solarbio), as indicated. Confocal images were captured using a Nikon A1 confocal microscope.

**Transmission electron microscopy (TEM)**

TEM was performed as described previously [22]. The cells and zebrafish eyes were fixed with 2.5% glutaraldehyde overnight at 4 °C and postfixed with 1% OsO4(02595-BA; SPI Chem) followed by dehydration through graded ethanol and absolute acetone. The tissues were then embedded in Spurr resin, sectioned to a thickness of 65 nm, and then stained with 2% uranyl acetate (02624-AB; SPI Chem) and alkaline lead citrate. TEM images were captured with a Hitachi Model H-7650 TEM.

**Computational Screening**

The data file for the structure of the human gigaxonin protein was downloaded from the AlphaFold database. All heterogeneous atoms were removed, followed by molecular docking. High-throughput virtual screening was performed by MCE Co., Ltd. (Shanghai, China) under HTVS, SP, and XP modes. The compounds were selected based on scoring values, conformation and structural diversity. Protein–ligand interactions were obtained by PyMOL version 1.7.4.5.

**Cellular thermal shift assay (CETSA)**

HLE cells were seeded in 10 cm dishes and incubated with 80 μM riboflavin or DMSO for 24 h. RIPA lysis buffer was added, and the respective lysates were divided into PCR tubes (100 μL). The lysates were individually heated at different temperatures (55, 60, 65, 70, 75, 80, and 85 °C) for 5 mins using a thermal cycler, then cooled for 3 mins at room temperature. The heated lysates were centrifuged at 12,000 g for 15 mins at 4 °C. The supernatants were transferred to new Eppendorf tubes for subsequent analysis by Western blotting.

**Statistical analyses**

The data were analyzed by GraphPad Prism 8.0 software and shown as the mean ± Standard Deviation (SD) of three independent experiments. The normality of the datasets was assessed using the Shapiro-Wilk normality test. The homogeneity of variances was examined using Levene’s test. If the
Our previous work established that the cx50-deficient zebrafish is a typical cataract model partially caused by defective autophagy [20]. We performed in vivo rescue experiments to further confirm the role of ATG16L1 in CX50-induced autophagy. ATG16L1 plasmids were injected into cx50-deficient zebrafish, and the severity of lens defects was evaluated at 72 hpf. As shown in Figures 2A and 2B, the ATG16L1 overexpression effectively relieved the lens differentiation defects in cx50-deficient zebrafish. The results were validated by TEM, showing increased autophagosome numbers in cx50-deficient zebrafish lenses with ATG16L1 overexpression (Figure 2C-D).

**ATG16L1 is mainly degraded by the ubiquitin-proteasome system (UPS)**

In mammalian cells, proteins undergo degradation through UPS or autophagy. Using inhibitors of these two pathways, we observed that ATG16L1 degradation was restored by the proteasomal inhibitor MG132 (Figure 3A-B), indicating that ATG16L1 turnover is mainly mediated by the UPS in HLE cells. Additionally, (Figure 3C-D), ATG16L1 in CX50-overexpressing HLE cells exhibited a longer half-life than in HLE cells under physiological conditions (Figure 3E-F), whereas CX50 knockdown HLE cells showed a shorter half-life (Figure 3G-H), indicating that CX50 may regulate ATG16L1 protein level by affecting its ubiquitin-dependent degradation.

Ubiquitination is described as the hallmark of protein degradation via the UPS in mammalian cells. IP assays showed that CX50 overexpression markedly reduced the ubiquitination level of ATG16L1 (Figure 4A). This finding was further validated by abnormal accumulation of ubiquitin in the center of the lens in cx50-deficient zebrafish (Figure 4B). It has previously been reported that different ubiquitin chains might exert diverse biological functions [23]. To determine the ubiquitination-modified ATG16L1, we co-transfected the HA-ATG16L1 and Myc-Ub (WT) with Myc-K48 or Myc-K63 plasmids in HEK293T cells (Figure 4C). Subsequently, using anti-K48 and K63-linkage polyubiquitin antibodies, we further confirmed that CX50 overexpression specifically decreased the K48-linked but not the K63-linked ubiquitination of ATG16L1 (Figure 4D-E). Additionally, IP assays employing a K48R ubiquitin mutant demonstrated attenuation of ATG16L1 ubiquitination mediated by CX50 (Figure 4F).

Collectively, these results verified that CX50 inhibits ATG16L1 degradation through K48-linked ubiquitination, inducing proteasomal degradation of target proteins.
Figure 1. ATG16L1 is crucial for lens autophagy induced by CX50. (A) Western blot analysis of LC3-I/II and CX50 in NC or CX50-knockdown HLE cells treated with or without 30 µM CQ for 6 h. (B) Quantification of LC3 levels, n = 3. Mann-Whitney test. (C) Representative images of LC3 and p62 puncta in NC and CX50-knockdown HLE cells treated with or without CQ (n = 3, > 30 cells per experiment), scale bar: 10 µm. (D) Quantification of LC3 and p62 puncta per cell, n = 3, > 30 cells per experiment (Mann-Whitney test). (E-G) mRNA (E) and protein levels (F and G) of ATG5, ATG12, and ATG16L1 in CX50 over-expressing HLE cells. (H) Immunoblot of Co-IP from Flag-CX50 with HA-ATG16L1 in HEK293T cells. WCL: whole cell lysate. (I) IP analysis of the interaction between CX50 and ATG16L1 in HLE cells. (J) Electron micrographs of HLE cells and (K) quantification of the AVs per cell. (L) Western blot analysis of LC3-II and HA in NC or CX50-knockdown HLE cells transfected with vector or ATG16L1. (M) Quantification analysis of LC3 levels, n = 3. Mean ± SD, *p < 0.05, **p < 0.01. N.S. not significant (Mann-Whitney test).
The interaction between ATG16L1 and E3 ubiquitin ligase gigaxonin is weakened by CX50 overexpression

Gigaxonin has been reported to be the only E3 ligase of ATG16L1 [19]. Co-IP assays revealed that overexpressed gigaxonin increased ATG16L1 ubiquitination (Figure 5A). However, CX50 overexpression significantly inhibited this process in vitro (Figure 5A). We investigated the ATG16L1-binding domains of CX50 to uncover the potential regulatory mechanism. ATG16L1 comprises three main domains: the N-terminal domain, the coiled-coil domain (CCD), and the C-terminal WD40 domain (WDD). We co-expressed Flag-CX50 with HA-tagged full-length ATG16L1 or one of four ATG16L1 deletion constructs (ATG16L1-M, ATG16L1-C, ATG16L1-ΔN and ATG16L1-ΔC) in 293T cells and performed CoIP assays (Figure 5B). As shown in Figure 5C, the ATG16L1-C and ATG16L1-ΔN, containing the WDD domains, exhibited affinity for CX50 similar to the full-length ATG16L1 protein, suggesting CX50 as a WDD-
interacting protein. Since gigaxonin was reported to interact with ATG16L1 via the WD40 domain [19], we explored the potential relationship between CX50 and gigaxonin. The results revealed that the dissociation of gigaxonin from ATG16L1 was proportional to the amount of CX50 added (Figure 5D). These data suggested that CX50 weakens the interaction between gigaxonin and ATG16L1, thereby inhibiting gigaxonin-mediated ubiquitination of ATG16L1.

Identification of riboflavin as a potential ATG16L1 ubiquitination regulator

E3 ubiquitin ligase is widely believed to be a viable drug target for various diseases. We explored its potential applications in cataract treatments by employing the crystal structure of E3 ligase gigaxonin and conducting the docking screening of a chemical library. We found a potential interaction between gigaxonin and riboflavin. As shown in Figure 6A, riboflavin binds to gigaxonin via amino acids ALA522, CYS570, TYR416, ALA463, VAL321, and ILE369. Subsequently, we confirmed the direct binding of riboflavin to gigaxonin using the cellular thermal shift assay (CETSA) in HLE cells. Figures 6B-C show that adding 80 µM riboflavin increased the stability of gigaxonin. These results suggested that riboflavin directly targets gigaxonin.

Co-IP assays showed that riboflavin could attenuate ATG16L1 ubiquitination (Figure 6D). Furthermore, riboflavin caused the dissociation of gigaxonin from ATG16L1 in a dose-dependent manner (Figure 6E). When the ATG16L1 protein expression and autophagy activity were examined with different concentrations of riboflavin, a dose-dependent increase in ATG16L1 and LC3 protein levels and a decrease in the p62 level were observed (Figure 6F-I). Consistently, riboflavin treatment led to a significant increase of autophagosome formation in HLE cells (Figure 6J-K). These data suggested that riboflavin can attenuate ATG16L1 ubiquitination, thus increasing the ATG16L1 protein level to promote autophagy in HLE cells.
**Figure 4.** K48-linked ubiquitination of ATG16L1 is mediated by CX50. (A) HEK293 cells were transfected with HA-ATG16L1 or Myc-Ub with or without Flag-CX50. After 24 h transfection, IP was performed with HA affinity gels on cells with or without MG132 treatment for 6 h, and ubiquitination was analyzed using anti-Myc. WCL: whole cell lysis. (B) Representative images showing the distribution of ATG16L1 and Ub in lenses from 72 hpf WT and cx50-deficient zebrafish. Scale bar: 10 µm. (C-F) The HEK293 cells were transfected with indicated plasmids for 24 h, and the IP using HA affinity gels was subjected to immunoblotting using the indicated antibodies.

### Riboflavin alleviates lens opacity in autophagy-related cataract models

Based on the promising *in vitro* results of riboflavin observed in cells, we investigated its efficacy *in vivo* in autophagy-related cataract models. First, we observed that riboflavin treatment prompted the denucleation and loss of the cytoskeleton and relieved lens opacity in cx50-deficient zebrafish (Figure 7A-B). Intriguingly, the cataract in the
**Discussion**

The lens, a transparent and avascular tissue, relies on programmed organelle degradation for development and maintenance, involving autophagy and other complex mechanisms. A significant finding of our study is that excessive degradation of ATG16L1 through the UPS, catalyzed by the E3 ubiquitin ligase gigaxonin, disrupts autophagy in the cx50-deficient cataract model. Additionally, we discovered that riboflavin could regulate ATG16L1 ubiquitination, promoting autophagy and reducing lens opacity in various autophagy-related cataract models, including cx50-deficient zebrafish, H2O2-induced cataract zebrafish, and cold-induced cataract rat models. These findings suggested ATG16L1 ubiquitination as a potential target for cataract treatment.

Autophagy plays a pivotal role in maintaining lens homeostasis [24]. It helps preserve transparency by eliminating organelles and acts as a protective mechanism against factors like ultraviolet radiation [25, 26]. Disruption of autophagy through the knockdown of core autophagy proteins or regulators, such as Atg5 and TBC1D20, has been linked to cataract development [10, 27]. Studies have shown that the absence of ATG5 in the lens leads to age-related cataracts due to the accumulation of damaged proteins and insoluble crystallins [27]. Moreover, oxidative stress triggers abnormal autophagic responses during the aging process of human lens epithelial cells [28, 29].

Our previous study demonstrated organelle degradation defects due to defective autophagy in the cx50 mutant zebrafish cataract model [20]. This study further validated impaired autophagic flux and autophagosome formation in HLE cells with CX50 deficiency. We provided in vitro and in vivo evidence supporting ATG16L1 as a downstream target for CX50 in regulating autophagy in the lens. Our finding was consistent with a previous report showing that connexins interact with specific ATGs in the plasma membrane, influencing basal autophagy function [30]. Additionally, CX43, another protein extensively expressed in the lens, was found to interact with ATG16L1 C-terminus, acting as a negative autophagy regulator [30].

---

**Figure 5.** The interaction between ATG16L1 and E3 ubiquitin ligase gigaxonin is weakened by CX50 overexpression. (A) HEK293 cells were transfected with indicated plasmids, and IP was analyzed with HA affinity gels and Western blotting. (B) ATG16L1 deletion constructs. (C) Immunoblots of immunoprecipitates from CX50-Flag with Atg16L1-HA, ATG16L1-M, ATG16L1-C, ATG16L1-ΔN, and ATG16L1-ΔC in HEK293T cells. WCL: whole cell lysis. (D) HEK293 cells were transfected with CX50-GFP, ATG16L1-HA, or gigaxonin-Flag for 24 h. ATG16L1-HA was then immunoprecipitated by anti-HA, and the associated gigaxonin and ATG16L1 were analyzed by Western blotting.
Figure 6. Identification of Riboflavin, a potential ATG16L1 ubiquitination regulator. (A) Modeling of riboflavin docking superimposed on gigaxonin, with the interacting gigaxonin amino acids represented by green sticks. (B) Cellular thermal shift assay of gigaxonin with riboflavin. (C) gigaxonin melting curves, n = 3. (D-E) HEK293 cells were transfected with indicated plasmids for 24 h; then, the cells were treated with DMSO or riboflavin for another 24 h. Western blots of immunoprecipitates with HA affinity gels. (F) Western blots of ATG16L1, LC3, and p62 protein levels in HLE cells treated with DMSO or riboflavin (40 µM and 80 µM), n = 3. (G-I) Quantification of ATG16L1, LC3, and p62 levels, n = 3 (Mann-Whitney test). (J-K) Electron micrographs of HLE cells and quantification of AVs per cell. Yellow arrows indicate autophagic vacuoles. ≥ 8 cells per experiment, scale bar: 1 µm. Mean ± SD, *p < 0.05, **p < 0.01 (Mann-Whitney test).
Figure 7. Riboflavin alleviates lens opacity in autophagy-related cataract models. (A) Representative images show the distribution of nuclei and F-actin in the lens of 72 hpf WT, cx50-deficient zebrafish, and cx50-deficient zebrafish treated with DMSO or riboflavin (80 µM). Scale bar: 10 µm. (B) Quantification of the severity of lens defects and the number of nuclei in lenses of each group (n > 25 zebrafish for each group) (Mann-Whitney test). (C) Representative images show that riboflavin alleviates lens opacity in the H2O2-induced cataract zebrafish model (n > 6 for each group). (D) Quantification of relief efficiency (Mann-Whitney test). (E) Representative images show that riboflavin alleviates cataract phenotype in cold-induced cataract rat models. (F) Quantification of transmittance (n > 5 for each group). Mean ± SD, *p < 0.05. N.S. not significant (Mann-Whitney test).

Notably, our in vivo experiments demonstrated that injecting the ATG16L1 plasmid increased autophagosome numbers, improved organelle degradation, and alleviated cataract symptoms in cx50-deficient zebrafish. These findings underlined the importance of ATG16L1 in cataract formation. ATG16L1, a key autophagy-related protein, plays significant roles in various diseases, from inflammatory bowel diseases, like Crohn’s disease, to neurodegenerative diseases, such as Alzheimer’s disease [31, 32]. Additionally, targeting the ATG16L1 axis was effective in modulating autophagy and overcoming drug resistance in cancer [33]. Our present study provides direct evidence of ATG16L1’s involvement in cataract formation.

Ubiquitination, a crucial post-translational modification, regulates the activities of autophagy-related proteins (e.g., Beclin1, ULK1, and p62) and key regulators (e.g., AKT, mTORC1, and AMPK) that control autophagic processes [34-39]. Ubiquitination involves a sequence of actions, including E1, E2, and E3 ubiquitin ligases, with E3 ligases determining substrate specificity [23, 40]. Recent studies have confirmed that gigaxonin E3 ligase regulates ATG16L1 ubiquitination, affecting autophagy in neurodegenerative diseases [19]. Our study found that ATG16L1 turnover predominantly occurs through the UPS process in HLE cells. The Co-IP assay showed that CX50 binds to ATG16L1, causing its dissociation from gigaxonin, reducing ATG16L1 K48 ubiquitination, and preserving its stability in the lens, thus identifying a potential mechanism for autophagy regulation in lens homeostasis.

E3 ubiquitin ligases are recognized as potential multi-drug targets for various diseases [41]. We employed the virtual screening technology, commonly used in other diseases, like liver cancer and colorectal cancer [42], to identify a potential interaction between gigaxonin and riboflavin, a water-soluble B vitamin [43]. Strikingly, our results confirmed that riboflavin could increase ATG16L1 levels by reducing its ubiquitination, promoting autophagy, and rescuing the cataract phenotype in the cx50-deficient zebrafish model. Also, we validated the
effectiveness of riboflavin treatment in two other cataract models associated with autophagy: the H2O2-induced cataract zebrafish model, characterized by over-activated oxidative stress-induced autophagy disturbance [29, 44, 45] and the cold-induced cataract rat model, where autophagy acts as a protective mechanism during hibernation [46, 47]. Our results showed that riboflavin effectively relieved lens opacity in all models tested. Notably, riboflavin deficiency has been reported in 80% of cataract patients [43]. As a safe drug with no known toxicity, riboflavin has been widely used in antioxidant and anti-inflammatory treatments for conditions like keratoconus, cheilitis, and sepsis. Our study suggests riboflavin as a potential therapeutic alternative for cataract treatment.

In summary, it is well-established that autophagy plays a role in cataract formation. Our results emphasize the critical role of ATG16L1 ubiquitination in modulating autophagy during cataract development, providing evidence for the intricate relationship between UPS and the autophagy pathway. Our study underscores the potential for drug design targeting E3 ubiquitin ligases to regulate autophagy, advancing the treatment of diseases associated with autophagy.

Abbreviations
ATG: Autophagy-related gene; CX50: connexin 50; CQ: chloroquine; CHX: cycloheximide; HLE cells: Human Lens Epithelial cells; Hpf: hours post-fertilization.

Supplementary Material
Supplementary figure, table, and information. https://www.thno.org/v14p3984s1.pdf

Acknowledgements
The authors thank the support from the National Natural Science Foundation of China (Grant No. 82171033, 82371037, 81970781 and 82201159), the Natural Science Foundation of Zhejiang Province (Grant No. LD21H120001) and the China Postdoctoral Science Foundation (Grant No. 2022M712761).

Ethics approval statement
All animal experiments in this study were conducted in accordance with the ARRIVE guidelines and were approved by Zhejiang University Animal Care and Use Committee protocols (No. 2019-069).

Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Competing Interests
The authors have declared that no competing interest exists.

References

https://www.thno.org


